FATE THERAPEUTICS INC (FATE) Stock Income Statement
NASDAQ:FATE - Nasdaq - US31189P1021 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 13.34M | 13.63M | 63.53M | 96.30M | 55.85M | |||
| Operating Expenses | 199.09M | 209.17M | 254.04M | 404.69M | 272.84M | |||
| Research and Development | 132.00M | 135.00M | 172.60M | 320.45M | 215.52M | |||
| Selling, General, and Administrative Expenses | 67.09M | 74.17M | 81.45M | 84.23M | 57.32M | |||
| Operating Income | -185.75M | -195.54M | -190.51M | -308.39M | -216.99M | |||
| Interest Income/Expense | 18.97M | 18.11M | 19.70M | 26.15M | 4.84M | |||
| Other Income/Expense | 5.64M | 5.91M | 9.88M | 520.00K | N/A | |||
| Non Recurring Items | N/A | -14.74M | N/A | N/A | N/A | |||
| Income Before Taxes | -175.88M | -186.26M | -160.93M | -281.72M | -212.15M | |||
| Income Tax | N/A | N/A | N/A | N/A | N/A | |||
| Net Income | -175.88M | -186.26M | -160.93M | -281.72M | -212.15M | |||
| EBITDA | -168.28M | -176.58M | -172.23M | -294.63M | -211.14M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.49 | -1.64 | -1.64 | -2.91 | -2.24 | |||
| Non GAAP EPS | -1.49 | -1.64 | -1.64 | -2.91 | -2.23 | |||
| Statistics | ||||||||
| Profit Margin | -1318.93% | -1366.46% | -253.30% | -292.54% | -379.86% | |||
| Operating Profit Margin | -1392.96% | -1434.52% | -299.86% | -320.24% | -388.52% | |||
All data in USD